Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials

Inicio | ¿Qué es? | Contacto

English | Català

Consultar RECERCAT

Por comunidades y
colecciones Por fecha Por autores Por títulos Por temas (CDU)

Consultar departamento

Por fecha Por autores Por títulos Por temas (CDU)

Estadisticas

Del documento Todo RECERCAT

Mi RECERCAT

Entrar Alertas por correo-e

Directorio de otros repositorios

RECERCAT Principal > Universitat de Barcelona > Institut d'lnvestigaciò Biomèdica de Bellvitge (IDIBELL) > Articles publicats en revistes (Institut d'lnvestigaciò Biomèdica de Bellvitge (IDIBELL)) > Visualizar documento

Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/147217

Título:	Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials
Autor/a:	Montal, Robert; Andreu Oller, Carmen; Bassaganyas, Laia; Esteban Fabró, Roger; Moran, Sebastian; Montironi, Carla; Moeini, Agrin; Pinyol, Roser; Peix, Judit; Cabellos, Laia; Villanueva, Augusto; Sia, Daniela; Mazzaferro, Vincenzo; Esteller, Manel; Llovet i Bayer, Josep Maria
Abstract:	The clinical utility of serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) is widely recognised. However, a clear understanding of the mechanisms of AFP overexpression and the molecular traits of patients with AFP-high tumours are not known. We assessed transcriptome data, whole-exome sequencing data and DNA methylome profiling of 520 HCC patients from two independent cohorts to identify distinct molecular traits of patients with AFP-high tumours (serum concentration?>?400?ng/ml), which represents an accepted prognostic cut-off and a predictor of response to ramucirumab. Those AFP-high tumours (18% of resected cases) were characterised by significantly lower AFP promoter methylation (p?
Materia(s):	-Càncer de fetge -Oncogènesi -Liver cancer -Carcinogenesis
Derechos:	(c) Montal et al., 2019
Tipo de documento:	Artículo Artículo - Versión publicada
Editor:	Nature Publishing Group
Compartir:

Mostrar el registro completo del ítem

Documentos relacionados

Otros documentos del mismo autor/a

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials

Montal, Robert; Andreu Oller, Carmen; Bassaganyas, Laia; Esteban Fabró, Roger; Moran, Sebastian; Montironi, Carla; Moeini, Agrin; Pinyol, Roser; Peix, Judit; Cabellos, Laia; Villanueva, Augusto; Sia, Daniela; Mazzaferro, Vincenzo; Esteller, Manel; Llovet i Bayer, Josep Maria

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials

An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents

Moeini, Agrin; Torrecilla, Sara; Tovar, Victoria; Montironi, Carla; Andreu Oller, Carmen; Peix, Judit; Higuera, Mónica; Pfister, Dominik; Ramadori, Pierluigi; Pinyol, Roser; Solé, Manel; Heikenwälder, Mathias; Friedman, Scott L.; Sia, Daniela; Llovet i Bayer, Josep Maria

Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma

Tovar, Victoria; Cornella, Helena; Moeini, Agrin; Vidal, Samuel; Hoshida, Yujin; Sia, Daniela; Peix, Judit; Cabellos, Laia; Alsinet, Clara; Torrecilla, Sara; Martinez Quetglas, Iris; Lozano Salvatella, Juan José; Desbois-Mouthon, Christele; Sole, Manel; Domingo-Domenech, Josep; Villanueva, Augusto; Llovet i Bayer, Josep Maria

Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma

Tovar, Victoria; Cornella, Helena; Moeini, Agrin; Vidal, Samuel; Hoshida, Yujin; Sia, Daniela; Peix, Judit; Cabellos, Laia; Alsinet, Clara; Torrecilla, Sara; Martínez Quetglas, Iris; Lozano Salvatella, Juan José; Desbois-Mouthon, Christele; Sole, Manel; Domingo Domènech, Josep Maria; Villanueva, Augusto; Llovet i Bayer, Josep Maria

Accesibilidad | Aviso legal | Política de Cookies | Documentos de uso interno

Coordinación

Patrocinio